• CRISPR Screens Reveal GRA12 as Key Toxoplasma Virulence Fact

  2026-05-26

  This study systematically identifies GRA12 as a secreted effector essential for Toxoplasma gondii virulence across diverse parasite strains and mouse subspecies. By leveraging in vivo CRISPR-Cas9 screens, the authors uncover mechanisms of immune evasion with broad implications for host-pathogen interaction research.

• Topotecan as a Topoisomerase I Inhibitor: Pharmacology and C

  2026-05-25

  This review details the pharmacological properties and clinical development of topotecan, a water-soluble camptothecin analogue targeting topoisomerase I. The findings clarify topotecan’s mechanism of action, clinical efficacy in solid tumors, and how its unique profile positions it alongside agents like cisplatin in oncology research.

• IPA-3: Transforming Pak1 Pathway Research for Translational

  2026-05-25

  This article explores the selective Pak1 inhibitor IPA-3, its mechanistic specificity, and strategic guidance for translational researchers. Drawing on recent virology and neuroscience evidence, it situates IPA-3 as a crucial tool in dissecting kinase pathways, highlights best practice protocol parameters, and provides a visionary outlook on its role in disease modeling and therapeutic innovation.

• FH1 Small Molecule: Transforming iPSC-Derived Hepatocyte Mat

  2026-05-24

  This article delivers a strategic and mechanistic perspective on how the FH1 small molecule (Catalog No. B3700) from APExBIO is catalyzing a new era in the maturation of iPS cell-derived hepatocytes. By anchoring the narrative in both fundamental biology and translational imperatives, it synthesizes current evidence, protocol optimization, and competitive context—while envisioning future directions that integrate optogenetic control and advanced gene therapy.

• Danazol (Danocrine): Mechanistic and Benchmark Insights for

  2026-05-23

  Danazol (Danocrine), a synthetic steroid with weak androgenic activity, is a proven inhibitor of steroidogenesis and a tool for hypothalamic–pituitary–gonadal axis modeling. Its mechanistic effects on androgen and estrogen pathways are well documented, facilitating its use in endocrine and prostate cancer research.

• PAD4-IN-2 TFA: Advancing Tumor-Targeted NET Inhibition Workf

  2026-05-22

  PAD4-IN-2 TFA enables precision inhibition of histone H3 citrullination and neutrophil extracellular trap (NET) formation, uniquely targeting tumor cells with minimal toxicity. Discover how this meta-phenylboronic acid-modified PAD4 inhibitor streamlines experimental design, empowers tumor immune microenvironment studies, and outperforms earlier PAD4 inhibitors in both selectivity and safety.

• Firefly Luciferase mRNA: Optimizing 5-moUTP Modified Reporte

  2026-05-22

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) sets a new benchmark for robust, low-immunogenicity bioluminescent reporter applications. Leverage advanced design for improved mRNA delivery, translation efficiency, and reproducibility—now with actionable troubleshooting and workflow insights.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Use Guide

  2026-05-21

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables fluorescence-based detection of goat IgG primary antibodies in immunocytochemistry, IHC, flow cytometry, and ELISA, offering robust signal amplification with minimal background. It should be used exclusively for detection of goat IgG in validated assay formats and is not suitable for non-goat primaries or non-immunoglobulin targets.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ) in Calcium Signaling

  2026-05-21

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) is redefining calcium signaling research and stem cell mobilization by enabling precise, reproducible inhibition of SERCA. This guide delivers actionable protocol enhancements, troubleshooting strategies, and data-driven insights for maximizing the impact of BHQ in vascular, regenerative, and muscle physiology studies.

• Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat

  2026-05-20

  The reference study reveals that certain kinase inhibitors not only block kinase activity but also promote dephosphorylation of p38α MAP kinase by stabilizing its activation loop in a conformation preferred by phosphatases. This dual-action mechanism offers new strategies for designing more potent and selective kinase inhibitors, with implications for targeted therapy and kinase signaling research.

• Evaluating Dye Models for Small Tissue Biopsies in Pathology

  2026-05-20

  This article reviews a 2023 study assessing various dyes for marking small tissue biopsies to prevent sample loss during histological processing. The findings highlight hematoxylin’s advantages for visibility and non-interference, with practical implications for optimizing biopsy workflows and sample integrity.

• Phosbind Biotin: Dinuclear Metal Complex Phosphate Binding i

  2026-05-19

  Phosbind Biotin revolutionizes Western Blot detection of phosphorylated proteins with its dinuclear metal complex phosphate binding, delivering sequence-independent, high-sensitivity results. This approach empowers signal transduction pathway research and overcomes the limitations of phospho-specific antibodies for robust protein phosphorylation analysis.

• Antidepressant Effects of Rotigotine in Preclinical Depressi

  2026-05-19

  This study systematically assesses the antidepressant-like properties of Rotigotine, a dopamine D2/D3 receptor agonist, across multiple validated rodent models of depression. It demonstrates dose-dependent behavioral improvements, highlighting new research avenues for dopaminergic modulation in neuropsychiatric disorders.

• HyperScribe™ T7 Kit: RNA Synthesis Precision for Metastasis

  2026-05-18

  Explore how the HyperScribe T7 High Yield RNA Synthesis Kit empowers high-fidelity RNA synthesis for advanced metastasis and anoikis resistance assays. This article uniquely connects molecular kit performance with assay design decisions revealed by recent metastasis research.

• Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization in CAC

  2026-05-18

  Liu et al. reveal that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine formulation, inhibits the progression of colitis-associated colorectal cancer (CAC) by stimulating macrophage polarization toward a tumor-suppressive M1 phenotype via the TLR4 pathway. This mechanistic insight clarifies JXY’s anti-tumor effects and highlights the importance of manipulating the tumor immune microenvironment for innovative CRC therapeutic strategies.

16439 records 7/1096 page Previous Next First page 上5页 678910 下5页 Last page